Cite
HARVARD Citation
Hoppe, J. et al. (2021). Long-term safety of lumacaftor–ivacaftor in children aged 2–5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study. Lancet. 9 (9), pp. 977-988. [Online].